Urea Metabolism in Man

Total Page:16

File Type:pdf, Size:1020Kb

Urea Metabolism in Man UREA METABOLISM IN MAN Mackenzie Walser, Leonard J. Bodenlos J Clin Invest. 1959;38(9):1617-1626. https://doi.org/10.1172/JCI103940. Research Article Find the latest version: https://jci.me/103940/pdf UREA METABOLISM IN MAN * By MACKENZIE WALSERt AND LEONARD J. BODENLOSt (From the Naval Medical Research Institute, National Naval Medical Center, Bethesda, Md. and the Laboratory of Kidney and Electrolyte Metabolism, National Heart Institute, National Institutes of Health, Bethesda, Md.) (Submitted for publication March 26, 1959; accepted May 14, 1959) Urea has long been considered to be meta- C"4-labeled urea containing 1 mc. of C14 per mMole was obtained from Volk Laboratories under authorization by bolically inert. However, recent studies with the Atomic Energy Commission. Both preparations were isotopic urea in several species of animals have prepared for use by dissolving in sterile saline solution. revealed that urea is hydrolyzed in the alimen- Tests for pyrogenicity and bacterial contamination were tary tract even when administered parenterally negative. (1-5). This breakdown is presumably due to The subjects were normal healthy volunteers who con- tinued their usual meals and activities during the studies. the action of bacterial urease, since urea metab- One glass of water per hour was ingested for four to eight olism can be eliminated or reduced to negligible hours following administration of labeled urea. Urinary proportions by the administration of antibiotics. catheters were not employed. In the studies reported herein, labeled urea was Measured portions of labeled urea (25 to 100 mg. of administered intravenously to normal subjects N" -urea or 2.5 Mc. of C"4-urea) were injected intravenously. At intervals, venous blood samples were obtained, and and the rate of extrarenal disposal was deter- immediately thereafter, the subjects voided. In the N'5 mined. Both N15- and C14-labeled materials were experiments, the urine samples were acidified immediately employed in order to minimize the problem of to prevent loss of ammonia. reincorporation of tracer atoms into urea. In The nitrogen content and atoms per cent excess N1" were the case of N'5, enriched ammonia produced by determined in urinary ammonia, urea and total nitrogen and in serum urea. Urine ammonia was isolated on per- urea hydrolysis in the gut becomes reincorpo- mutit which was then washed five times with distilled rated into newly formed urea. In the case of water. Ammonia-free urine and a tungstic acid filtrate of C14, recent evidence (6) suggests that reincorpo- serum were treated with urease according to the method ration into urea of labeled CO2, formed by bac- of Van Slyke and Cullen (8). A sample of urine was also terial ureolysis in the gut, may also occur; a subjected to Kjeldahl digestion overnight. After the addi- the tion of alkali, ammonia from these various fractions was conclusion supported by present experiments. steam distilled into boric acid solution and titrated with Despite these limitations, the results indicate 0.1 N HCl. The recovery of urea was determined simul- that 15 to 30 per cent of the urea being synthe- taneously in each experiment and averaged 98 per cent. sized in normal subjects is continually being The solutions remaining after titration were evaporated to destroyed. This breakdown can be eliminated a small volume and allowed to react with sodium hypo- by oral administration of neomycin. bromite in Rittenberg tubes. The atoms per cent N" in the evolved nitrogen gas was determined in the mass spec- trometer (Consolidated model 21-201). Atoms per cent METHODS excess N"6 was determined by subtracting values for atoms Urea containing 60.9 atoms per cent N"5 was synthesized per cent N"6 in control samples of blood and urine. Com- by the ammonolysis of diphenyl carbonate (7) and purified pared to an ammonium chloride standard, the control by recrystallization.' The resulting product had a melting samples contained a biological excess of N"6 of less than point of 130° C. (uncorrected). The nitrogen content was 0.004 atoms per cent. The maximum error of the N"6 46.7 per cent (calculated 46.7 per cent). analyses was a0.002 atoms per cent. In the C" experiments, total urea was determined by * An abstract of this work has been published (Urea the method of Conway (9). C"4-urea was determined as breakdown in normal man. J. clin. Invest. 1957, 36, 933). follows: aliquots of blood or urine were acidified with HCl The opinions presented herein are those of the authors and and shaken with a few drops of caprylic alcohol in order to do not necessarily reflect the views of the United States remove all bicarbonate. Sufficient alkali was added to Navy. restore the pH to approximately 7, and aliquots were placed t Formerly Lieutenant, Medical Corps, USNR. Pres- in 50 ml. flasks containing a center well. One ml. of 3 ent address: Johns Hopkins School of Medicine, Balti- per cent urease solution (Sigma Chemical Co.) and 1 ml. more, Md. of phosphate buffer, pH 7.2, were added and the flasks Lieutenant Commander, Medical Service Corps, USN. were stoppered. After 20 minutes shaking at 370 C., dilute Dr. W. J. McCarville kindly carried out this synthesis. H2SO4 was injected through the stopper. Shaking was 1617 1618 MACKENZIE WALSER AND LEONARD J. BODENLOS continued for another hour. In the earlier experiments, designate the difference between the extrapolated intercept the center well contained 25 per cent NaOH, C02-free, value, M., and the amount injected, M (which is the inter- which was transferred to centrifuge tubes, mixed with 10 cept value which would have obtained if equilibration had ml. 1 per cent BaCl2 in C02-free water, and centrifuged. occurred instantaneously): The precipitated barium carbonate was washed with C02- Mo= M - x. free 50 per cent ethanol, suspended in 95 per cent ethanol 4) and transferred to weighed planchets. The planchets were Substituting in Equation 3, we have, for any time greater dried, reweighed and counted in a flow counter for a total than the equilibration period: of 10,000 counts. After correction for background and Mt = (M - x) e-(A vP)t. 5) self-absorption, the results were expressed in terms of an The apparent volume of aliquot of the injected solution analyzed simultaneously. distribution, V, is given by: In M0 M-x the later experiments, the center well contained 0.2 VP= P 6) ml. of Hyamine®, 0.5 N. This was transferred with the PO Po aid of 1.5 ml. toluene to specimen vials, mixed with 15 ml. where po is the intercept value of the plasma concentration toluene containing diphenyl oxazole, 1 N, capped, cooled of tracer. The plasma concentration of tracer at time t, and counted in a Tri-Carb liquid scintillation counter for pt (where t is greater than the equilibration period), is a total of 5,000 counts. The results were expressed in terms of an aliquot of the injected solution analyzed pt = po e-(AIVP)t. 7) simultaneously. Therefore, po and A/VP may be derived from observa- tions of pt. In order to calculate V it is necessary to have CALCULATIONS an estimate of x, as Equation 6 shows. If the rate of excretion of native substance, U, is large When a trace quantity, M, of a substance normally with respect to the rate of metabolism, F, then a good present in the blood is injected intravenously, the tracer estimate of x can be obtained by observing the excretion molecules become mixed with the native molecules present of tracer, as shown in the following derivation. in the blood and in the interstitial fluid. Under certain The rate of renal (or renal plus extrarenal) excretion of conditions the tracer molecules eventually become evenly tracer, ut, is determined by the fact that the specific mixed with all of the native substance present in the body activities (or, in the case of stable isotopes, the atoms per in an exchangeable form. Although this completely uni- cent excess) in blood and urine are equal with the qualifi- form ratio of tracer to native molecules is theoretically cations noted below: in a closed for unobtainable except system, practical pur- Ut _ Pt poses an equilibrium distribution may be obtained because U P, 8) the rates of excretion and/or metabolic destruction are slow relative to the rate of equilibration. Substituting for pt from Equation 7, If the rates of formation, A, excretion, U, and metabolic destruction, F, of the native substance remain constant ut = -F;poPo e(A/VP)t 9) during the period of observation, and if The total amount of tracer, S, excreted up to time t (pro- A = U +F, 1) vided that t is greater than the equilibration period) is then the plasma concentration, P, of native substance will therefore: remain constant, as will VP, the total amount in the body, where V is its apparent volume of distribution (assuming S = X + A = X+ lUVPEl -e-(A/VP)t]. 10) that V does not change). Following equilibration of injected tracer, the amount, Dividing by M, the amount of tracer injected, we have of tracer at will decline S x + UVp [1 Mt, remaining any given time, t, - e-(A/VP)t]. 11) at a rate given by the turnover rate of native substance, MM AM A/VP. It is assumed here that no tracer returns to the This equation can be treated as a straight line function of pool once metabolized: two variables, viz., S/M and [1 -e-(A/VP)tJ, following the suggestion of Berkson, Keating, Power and McConahey - dMt/dt = V Mt. 2) (10).
Recommended publications
  • NINDS Custom Collection II
    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
    [Show full text]
  • Antibiotics and Antibacterials, General
    B. Sulfamethoxydiazine (Sulfameter, Sulla) IX. TOXICITY AND SIDE EFFECTS: C. Sulfadimethoxine (Madribon) A. Fever D. Sulphormethoxine-Very long-acting; thera- B. Rash, urticaria peutic blood levels for 1 week. C. Cyanosis, methemoglobinemia D. Nausea, vomiting, diarrhea V. POORLY ABSORBED SULFONAMIDES: E. Hepatitis, jaundice for local use in the intestinal tract only. F. Hematuria, albuminuria, crystalluria, toxic A. Succinylsulfathiazole (Sulfasuxidine): nephritis. 1. Dosage-3.0 Gm q 4 h p.o. G. Headache, mental depression, psychosis, 2. Maximum effect usually not achieved un- peripheral neuritis. til 7th day of therapy. H. Leukopenia, agranulocytosis, purpura, aplas- B. Phthalylsulfathiazole (Sulfathalidine): tic anemia, hypoprothrombinemia, hemolytic ane- 1. Dosage-1.5 Gmq4hp.o. mia. 2. Double this dosage in the presence of I. Severe hypersensitivity reactions - anaphy- diarrhea. laxis, periarteritis nodosa and other collagen dis- 3. Effect produced in 5-7 days. eases, Stevens-Johnson syndrome. C. Para-nitrosulfathiazole (Nisulfazole): Used X. only for intrarectal instillation in treatment of PRECAUTIONS: proctitis or non-specific colitis. A. Keep careful record of urine output - try to maintain output of at least 1200-1500 ml/24 VI. TOPICAL SULFONAMIDES: hrs. B. Alkalinization of urine-sodium bicarbonate A. Mafenide (Sulfamylon): Used on skin as (12-15 Gm/day) may be used for this purpose 10% cream. Unlike other sulfonamides, effective when full systemic doses of sulfonamides are used, in presence of pus and necrotic tissue and does not when there is difficulty in being sure of adequate sensitize readily when used topically. Of value in fluid intake and output, and when such adjunctive prevention and therapy of burn infection due to therapy is not contraindicated.
    [Show full text]
  • A Screening-Based Approach to Circumvent Tumor Microenvironment
    JBXXXX10.1177/1087057113501081Journal of Biomolecular ScreeningSingh et al. 501081research-article2013 Original Research Journal of Biomolecular Screening 2014, Vol 19(1) 158 –167 A Screening-Based Approach to © 2013 Society for Laboratory Automation and Screening DOI: 10.1177/1087057113501081 Circumvent Tumor Microenvironment- jbx.sagepub.com Driven Intrinsic Resistance to BCR-ABL+ Inhibitors in Ph+ Acute Lymphoblastic Leukemia Harpreet Singh1,2, Anang A. Shelat3, Amandeep Singh4, Nidal Boulos1, Richard T. Williams1,2*, and R. Kiplin Guy2,3 Abstract Signaling by the BCR-ABL fusion kinase drives Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL) and chronic myelogenous leukemia (CML). Despite their clinical activity in many patients with CML, the BCR-ABL kinase inhibitors (BCR-ABL-KIs) imatinib, dasatinib, and nilotinib provide only transient leukemia reduction in patients with Ph+ ALL. While host-derived growth factors in the leukemia microenvironment have been invoked to explain this drug resistance, their relative contribution remains uncertain. Using genetically defined murine Ph+ ALL cells, we identified interleukin 7 (IL-7) as the dominant host factor that attenuates response to BCR-ABL-KIs. To identify potential combination drugs that could overcome this IL-7–dependent BCR-ABL-KI–resistant phenotype, we screened a small-molecule library including Food and Drug Administration–approved drugs. Among the validated hits, the well-tolerated antimalarial drug dihydroartemisinin (DHA) displayed potent activity in vitro and modest in vivo monotherapy activity against engineered murine BCR-ABL-KI–resistant Ph+ ALL. Strikingly, cotreatment with DHA and dasatinib in vivo strongly reduced primary leukemia burden and improved long-term survival in a murine model that faithfully captures the BCR-ABL-KI–resistant phenotype of human Ph+ ALL.
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • Insights of Taste Masking from Molecular Interactions and Microstructures of Microspheres
    Insights of Taste Masking from Molecular Interactions and Microstructures of Microspheres Item Type Thesis Authors Guo, Zhen Publisher University of Bradford Rights <a rel="license" href="http://creativecommons.org/licenses/ by-nc-nd/3.0/"><img alt="Creative Commons License" style="border-width:0" src="http://i.creativecommons.org/l/by- nc-nd/3.0/88x31.png" /></a><br />The University of Bradford theses are licenced under a <a rel="license" href="http:// creativecommons.org/licenses/by-nc-nd/3.0/">Creative Commons Licence</a>. Download date 17/11/2019 12:36:58 Link to Item http://hdl.handle.net/10454/17420 Insights of Taste Masking from Molecular Interactions and Microstructure of Microspheres Zhen Guo Submitted for the Degree of Doctor of Philosophy Institute of Cancer Therapeutics, Faculty of Life Sciences, University of Bradford 2017 Abstract Zhen Guo Insights of Taste Masking from Molecular Interactions and Microstructures of Microspheres Keywords: Taste Masking, Cyclodextrin, Lipid Microspheres, Kinetics, Synchrotron Radiation, Surface Plasmon Resonance Imaging, High Performance Affinity Chromatography The effects of taste masking are determined by interactions between drug and excipients as well as the microstructures of the particulate drug delivery systems (DDS). Cyclodextrin (CD) is a widely used taste masking agent, to which the relationship between kinetic parameters (Ka and Kd) of a drug and taste masking remains unexplored, which is investigated for the first time in this study. A data base of the kinetic parameters for drug-CD was established by Surface Plasmon Resonance Imaging (SPRi) and High Performance Affinity Chromatography (HPAC). Combined with the electronic tongue, Ka and Kd based models for the taste masking effect of HP-β-CD were successfully established and applied to the prediction of taste masking effects.
    [Show full text]
  • Symmetry® Columns Applications Notebook
    Symmetry ® Columns Applications Notebook Symmetry® SymmetryShield™ Symmetry300™ SymmetryPrep™ Intelligent Speed (IS™) www.waters.com Symmetry® Columns Setting the Standard for Reproducibility As today’s chemists establish new Unmatched Year-to-year Reproducibility analytical methods for the latest pharmaceu- ® ® tical and biopharmaceutical products, the Column: Symmetry C18, Instrumentation: Waters Alliance HT 2795 selection of a reproducible HPLC column is 4.6 x 150 mm, 5 µm Waters 996 PDA detector Mobile Phase A: H2O Sampling Rate: 5 pts./sec essential. The selected column needs to Mobile Phase B: MeCN Mobile Phase C: pH 3.75; 100 mM provide the same chromatographic results NH4COOH in H2O Flow Rate: 1.4 mL/min over the life of the new drug product. Isocratic: 30% A; 60% B; 10% C RSD’s for Retention Times Injection Volume: 5.0 µL ® 1. Terbinafine HCl 0.7% Symmetry columns demonstrate superior Temperature: 30 °C reproducibility over many years. Batches Detection: UV @ 233 nm 2. Ibuprofen 0.8% 3. Lovastatin 0.6% randomly selected over the past 5 years 4. Simvastatin 0.7% demonstrate excellent reproducibility in the example shown. Reproducibility is our number one priority in supplying Symmetry® columns. This excellent reproducibility is a result of our commitment Batch 136 (1998) to maintaining the tightest specifications in the HPLC column industry. Symmetry® columns Batch 142 (1998) are engineered with high purity raw materials, tightly controlled manufacturing Batch 149 (1999) processes and column packing procedures that provide today’s scientists with the best, Batch 151 (2000) most reproducible HPLC column available. Batch 156 (2001) Our goal is to supply a family of HPLC columns that you can rely on for rugged and Minutes robust methods.
    [Show full text]
  • (ESI) for Integrative Biology. This Journal Is © the Royal Society of Chemistry 2017
    Electronic Supplementary Material (ESI) for Integrative Biology. This journal is © The Royal Society of Chemistry 2017 Table 1 Enriched GO terms with p-value ≤ 0.05 corresponding to the over-expressed genes upon perturbation with the lung-toxic compounds. Terms with corrected p-value less than 0.001 are shown in bold. GO:0043067 regulation of programmed GO:0010941 regulation of cell death cell death GO:0042981 regulation of apoptosis GO:0010033 response to organic sub- stance GO:0043068 positive regulation of pro- GO:0010942 positive regulation of cell grammed cell death death GO:0006357 regulation of transcription GO:0043065 positive regulation of apop- from RNA polymerase II promoter tosis GO:0010035 response to inorganic sub- GO:0043066 negative regulation of stance apoptosis GO:0043069 negative regulation of pro- GO:0060548 negative regulation of cell death grammed cell death GO:0016044 membrane organization GO:0042592 homeostatic process GO:0010629 negative regulation of gene ex- GO:0001568 blood vessel development pression GO:0051172 negative regulation of nitrogen GO:0006468 protein amino acid phosphoryla- compound metabolic process tion GO:0070482 response to oxygen levels GO:0045892 negative regulation of transcrip- tion, DNA-dependent GO:0001944 vasculature development GO:0046907 intracellular transport GO:0008202 steroid metabolic process GO:0045934 negative regulation of nucle- obase, nucleoside, nucleotide and nucleic acid metabolic process GO:0006917 induction of apoptosis GO:0016481 negative regulation of transcrip- tion GO:0016125 sterol metabolic process GO:0012502 induction of programmed cell death GO:0001666 response to hypoxia GO:0051253 negative regulation of RNA metabolic process GO:0008203 cholesterol metabolic process GO:0010551 regulation of specific transcrip- tion from RNA polymerase II promoter 1 Table 2 Enriched GO terms with p-value ≤ 0.05 corresponding to the under-expressed genes upon perturbation with the lung-toxic compounds.
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2019 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Common Study Protocol for Observational Database Studies WP5 – Analytic Database Studies
    Arrhythmogenic potential of drugs FP7-HEALTH-241679 http://www.aritmo-project.org/ Common Study Protocol for Observational Database Studies WP5 – Analytic Database Studies V 1.3 Draft Lead beneficiary: EMC Date: 03/01/2010 Nature: Report Dissemination level: D5.2 Report on Common Study Protocol for Observational Database Studies WP5: Conduct of Additional Observational Security: Studies. Author(s): Gianluca Trifiro’ (EMC), Giampiero Version: v1.1– 2/85 Mazzaglia (F-SIMG) Draft TABLE OF CONTENTS DOCUMENT INFOOMATION AND HISTORY ...........................................................................4 DEFINITIONS .................................................... ERRORE. IL SEGNALIBRO NON È DEFINITO. ABBREVIATIONS ......................................................................................................................6 1. BACKGROUND .................................................................................................................7 2. STUDY OBJECTIVES................................ ERRORE. IL SEGNALIBRO NON È DEFINITO. 3. METHODS ..........................................................................................................................8 3.1.STUDY DESIGN ....................................................................................................................8 3.2.DATA SOURCES ..................................................................................................................9 3.2.1. IPCI Database .....................................................................................................9
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2009/0324736A1 Johnson Et Al
    US 20090324736A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0324736A1 Johnson et al. (43) Pub. Date: Dec. 31, 2009 (54) METHODS OF TREATING BOWEL DISEASES (22) Filed: May 7, 2009 BY ADMINISTERING ABOWEL CLEANSER AND AN ANTIBOTC Related U.S. Application Data (60) Provisional application No. 61/051,341, filed on May (75) Inventors: Lorin Johnson, Palo Alto, CA 7, 2008. (US); William Forbes, Raleigh, NC (US); Stephana Patton, San Publication Classification Francisco, CA (US) (51) Int. Cl. Correspondence Address: A633/42 (2006.01) EDWARDS ANGELL PALMER & DODGE LLP A633/14 (2006.01) P.O. BOX SS874 A63L/439 (2006.01) BOSTON, MA 02205 (US) (52) U.S. Cl. .......................... 424/606: 424/679:514/279 (57) ABSTRACT (73) Assignee: Salix Pharmaceuticals, Ltd., Morrisville, NC (US) The present invention relates to formulations and kits for the treatment of bowel disease, to their use in medicinal prepa (21) Appl. No.: 12/437,232 rations and to therapeutic methods thereof. US 2009/032473.6 A1 Dec. 31, 2009 METHODS OF TREATING BOWEL DISEASES 0009. According to one embodiment, the GI cleanser BY ADMINISTERING ABOWEL CLEANSER comprises one or more of a PEG based composition or a AND AN ANTIBOTC Sodium phosphate based composition. 0010. According to one embodiment, the GI cleanser RELATED APPLICATIONS comprises polyethylene glycol (PEG), sodium sulfate, 0001. This application claims the benefit of U.S. Provi Sodium chloride, potassium chloride, and ascorbic acid. sional Application No. 61/051,341, filed May 7, 2008, the 0011. According to one embodiment, the GI cleanser is entire contents of which is expressly incorporated herein by supplied as two pouch A's comprising 100 grams of PEG reference.
    [Show full text]